GlassScriptPhysician profile
Catherine D Coates
NPI 1811441082
$5,025.46
in general payments reported to CMS, 2019-2025
44 companies · $929 in 2025
The $929 reported for 2025 was more than what 86% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $939 · 2023: $1,152 · 2024: $1,184 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,179.20 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,513.95 | 2021-2025 | |
| Astellas Pharma US INC | $450.58 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $350.70 | 2021-2025 | |
| Glaxosmithkline, LLC. | $274.06 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Gilead Sciences, INC. | $206.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $195.98 | 2021-2024 | Capvaxive, Gardasil 9, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.36 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $161.88 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $150.88 | 2022-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $150.35 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $122.91 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $94.59 | 2023 | |
| Nestle Healthcare Nutrition INC. | $92.37 | 2021-2022 | |
| Boston Scientific Corporation | $90.74 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $80.36 | 2022-2025 | Mounjaro, Jardiance, Emgality |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Coates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.